中国生物制药 1 类新药国内启动“头对头”III 期临床

丁香园 Insight 数据库
Oct 14

10 月 14 日,中国药物临床试验登记与信息公示平台显示,中国生物制药旗下南京正大天晴1 类新药NTQ5082 胶囊登记了一项治疗阵发性睡眠性血红蛋白尿症(PHN)的III 期临床。截图来源:药物临床试验登记与信息公示平台本次启动的是一项多中心、随机、开放、阳性药对照的 III 期临床试验,旨在评估 NTQ5082 胶囊相较于依库珠单抗注射液(全球首个 C5 补体抑制剂)治疗PNH患者的有效性和...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10